keyword
MENU ▼
Read by QxMD icon Read
search

Synagis

keyword
https://www.readbyqxmd.com/read/27663736/rational-design-of-a-kv1-3-channel-blocking-antibody-as-a-selective-immunosuppressant
#1
Rongsheng E Wang, Ying Wang, Yuhan Zhang, Chase Gabrelow, Yong Zhang, Victor Chi, Qiangwei Fu, Xiaozhou Luo, Danling Wang, Sean Joseph, Kristen Johnson, Arnab K Chatterjee, Timothy M Wright, Vân T B Nguyen-Tran, John Teijaro, Argyrios N Theofilopoulos, Peter G Schultz, Feng Wang
A variable region fusion strategy was used to generate an immunosuppressive antibody based on a novel "stalk-knob" structural motif in the ultralong complementary-determining region (CDR) of a bovine antibody. The potent Kv1.3 channel inhibitory peptides Moka1-toxin and Vm24-toxin were grafted into different CDRs of the humanized antibodies BVK and Synagis (Syn) using both β-sheet and coiled-coil linkers. Structure-activity relationship efforts led to generation of the fusion protein Syn-Vm24-CDR3L, which demonstrated excellent selectivity and potency against effector human memory T cells (subnanomolar to picomolar EC50 values)...
October 11, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27439110/palivizumab-for-prophylaxis-against-respiratory-syncytial-virus-infection-in-children-with-cystic-fibrosis
#2
REVIEW
Karen A Robinson, Olaide A Odelola, Ian J Saldanha
BACKGROUND: Respiratory syncytial virus infection causes acute lung infection in infants and young children worldwide, resulting in considerable morbidity and mortality. Children with cystic fibrosis are prone to recurrent lung inflammation, bacterial colonisation and subsequent chronic airway disease, putting them at risk for severe respiratory syncytial virus infections requiring intensive care and respiratory support. No treatment currently exists, hence prevention is important. Palivizumab is effective in reducing respiratory syncytial virus hospitalisation rates and is recommended for prophylaxis in high-risk children with other conditions...
July 20, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27258388/discovery-and-characterization-of-phage-display-derived-human-monoclonal-antibodies-against-rsv-f-glycoprotein
#3
Zhifeng Chen, Lan Zhang, Aimin Tang, Cheryl Callahan, Pavlo Pristatsky, Ryan Swoyer, Pedro Cejas, Debbie Nahas, Jennifer Galli, Scott Cosmi, Daniel DiStefano, Van M Hoang, Andrew Bett, Danilo Casimiro, Kalpit A Vora
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants, the elderly and in immunosuppressed populations. The vast majority of neutralizing antibodies isolated from human subjects target the RSV fusion (F) glycoprotein, making it an attractive target for the development of vaccines and therapeutic antibodies. Currently, Synagis® (palivizumab) is the only FDA approved antibody drug for the prevention of RSV infection, and there is a great need for more effective vaccines and therapeutics...
2016: PloS One
https://www.readbyqxmd.com/read/25551881/medication-highlights-new-recommendations-for-palivizumab-synagis
#4
Jody Ridky
No abstract text is available yet for this article.
November 2014: Neonatal Network: NN
https://www.readbyqxmd.com/read/24851825/palivizumab-for-prophylaxis-against-respiratory-syncytial-virus-infection-in-children-with-cystic-fibrosis
#5
REVIEW
Karen A Robinson, Olaide A Odelola, Ian J Saldanha
BACKGROUND: Respiratory syncytial virus infection causes acute lung infection in infants and young children worldwide, resulting in considerable morbidity and mortality. Children with cystic fibrosis are prone to recurrent lung inflammation, bacterial colonisation and subsequent chronic airway disease, putting them at risk for severe respiratory syncytial virus infections requiring intensive care and respiratory support. No treatment currently exists, hence prevention is important. Palivizumab is effective in reducing respiratory syncytial virus hospitalisation rates and is recommended for prophylaxis in high-risk children with other conditions...
2014: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/24812523/respiratory-syncytial-virus-current-and-emerging-treatment-options
#6
REVIEW
Tiffany L Turner, Benjamin T Kopp, Grace Paul, Lindsay C Landgrave, Don Hayes, Rohan Thompson
Respiratory syncytial virus (RSV) is an important respiratory pathogen in infants and children worldwide. Although RSV typically causes mild upper respiratory infections, it frequently causes severe morbidity and mortality, especially in premature infants and children with other chronic diseases. Treatment of RSV is limited by a lack of effective antiviral treatments; however, ribavirin has been used in complicated cases, along with the addition of intravenous immune globulin in specific patients. Vaccination strategies for RSV prevention are heavily studied, but only palivizumab (Synagis(®)) has been approved for use in the United States in very select patient populations...
2014: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/24711420/glycan-variants-of-a-respiratory-syncytial-virus-antibody-with-enhanced-effector-function-and-in-vivo-efficacy
#7
Andrew Hiatt, Natasha Bohorova, Ognian Bohorov, Charles Goodman, Do Kim, Michael H Pauly, Jesus Velasco, Kevin J Whaley, Pedro A Piedra, Brian E Gilbert, Larry Zeitlin
Respiratory syncytial virus (RSV) can cause devastating lower respiratory tract infections in preterm infants or when other serious health problems are present. Immunoprophylaxis with palivizumab (Synagis), a humanized IgG1 mAb, is the current standard of care for preventing RSV infection in at-risk neonates. We have explored the contribution of effector function to palivizumab efficacy using a plant-based expression system to produce palivizumab N-glycan structure variants with high homogeneity on different antibody isotypes...
April 22, 2014: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/24362693/respiratory-syncytial-virus-disease-prevention-and-treatment
#8
Helen Y Chu, Janet A Englund
Respiratory syncytial virus (RSV) is one of the most clinically important viruses infecting young children, the elderly, and the immunocompromised. Over the past decade, the most significant advance in the prevention of RSV disease has been the development of high-titered antibody products. Infection control is the only other strategy to prevent RSV disease. A humanized monoclonal antibody directed against the fusion (F) protein palivizumab, (Synagis®, MedImmune, Inc., Gaithersburg, MD), is given routinely on a monthly basis to premature infants and young children less than 24 months of age with underlying medical problems including prematurity, chronic lung disease, or cardiac disease to prevent RSV disease and hospitalization...
2013: Current Topics in Microbiology and Immunology
https://www.readbyqxmd.com/read/24056377/-palivizumab-for-respiratory-syncytial-virus-disease
#9
G Carrera, R D'alterio, G Leone, C Zambetti
AIM: Palivizumab (Synagis, Abbott) is a humanized monoclonal antibody of IgG class currently used for prophylaxis of respiratory syncytial virus (RSV) infection. It neutralises the protein F of RSV, which allows the virus to penetrate inside the host cell and subsequently to form syncytia, causing clinical manifestations. Based on that, our aim was to assess if an early administration of palivizumab during RSV infection could positively modify the infection course, hence providing a therapeutic effect...
October 2013: Minerva Pediatrica
https://www.readbyqxmd.com/read/23749572/detecting-respiratory-syncytial-virus-using-nanoparticle-amplified-immuno-pcr
#10
Jonas W Perez, Nicholas M Adams, Grant R Zimmerman, Frederick R Haselton, David W Wright
Early-stage detection is essential for effective treatment of pediatric virus infections. In traditional -immuno-PCR, a single antibody recognition event is associated with one to three DNA tags, which are subsequently amplified by PCR. In this protocol, we describe a nanoparticle-amplified immuno-PCR assay that combines antibody recognition of traditional ELISA with a 50-fold nanoparticle valence amplification step followed by amplification by traditional PCR. The assay detects a respiratory syncytial virus (RSV) surface fusion protein using a Synagis antibody bound to a 15 nm gold nanoparticle co-functionalized with thiolated DNA complementary to a hybridized 76-base Tag DNA...
2013: Methods in Molecular Biology
https://www.readbyqxmd.com/read/23737087/palivizumab-for-prophylaxis-against-respiratory-syncytial-virus-infection-in-children-with-cystic-fibrosis
#11
REVIEW
Karen A Robinson, Olaide A Odelola, Ian J Saldanha, Naomi A McKoy
BACKGROUND: Respiratory syncytial virus infection causes acute lung infection in infants and young children worldwide, resulting in considerable morbidity and mortality. Children with cystic fibrosis are prone to recurrent lung inflammation, bacterial colonisation and subsequent chronic airway disease, putting them at risk for severe respiratory syncytial virus infections requiring intensive care and respiratory support. No treatment currently exists, hence prevention is important. Palivizumab is effective in reducing respiratory syncytial virus hospitalisation rates and is recommended for prophylaxis in high-risk children with other conditions...
2013: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/23575729/human-monoclonal-antibodies-as-candidate-therapeutics-against-emerging-viruses-and-hiv-1
#12
REVIEW
Zhongyu Zhu, Ponraj Prabakaran, Weizao Chen, Christopher C Broder, Rui Gong, Dimiter S Dimitrov
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1)...
April 2013: Virologica Sinica
https://www.readbyqxmd.com/read/23530423/-experience-of-palivizumab-in-prophylaxis-of-respiratory-syncytial-viral-infection-in-premature-children-with-bronchopulmonary-dysplasia
#13
RANDOMIZED CONTROLLED TRIAL
G A Aliamovskaia, E S Keshinian
The data on prophylaxis efficacy of the Palivizumab (synagis) against respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia are shown in the article. No side-effects, good tolerance and decrease of the frequency of bronchopulmonary dysplasia relapses and other viral diseases in whole in such children were registered.
2012: Vestnik Rossiĭskoĭ Akademii Meditsinskikh Nauk
https://www.readbyqxmd.com/read/23461427/evaluation-of-a-novel-web-based-prior-approval-application-for-palivizumab-prophylaxis-of-respiratory-syncytial-virus-in-a-state-medicaid-program
#14
Kristin Lundeen, Trista Pfeiffenberger, Julie Jacobson Vann, Timothy O'Brien, Charlene Sampson, Steven Wegner
BACKGROUND: Recent disproportionate increases in use of specialty medications, such as palivizumab (Synagis), compared with steady utilization of traditional medication use, have prompted complex utilization management strategies that require frequent evaluation to facilitate cost-effectiveness while preserving patient access. Clinical criteria utilized by North Carolina (NC) Medicaid for use of palivizumab for respiratory syncytial virus (RSV) prophylaxis are consistent with the most recent guidelines published in the Red Book: Report of the Committee on Infectious Diseases...
March 2013: Journal of Managed Care Pharmacy: JMCP
https://www.readbyqxmd.com/read/23396091/prophylactic-and-therapeutic-testing-of-nicotiana-derived-rsv-neutralizing-human-monoclonal-antibodies-in-the-cotton-rat-model
#15
Larry Zeitlin, Ognian Bohorov, Natasha Bohorova, Andrew Hiatt, Do H Kim, Michael H Pauly, Jesus Velasco, Kevin J Whaley, Dale L Barnard, John T Bates, James E Crowe, Pedro A Piedra, Brian E Gilbert
Severe lower respiratory tract infection in infants and small children is commonly caused by respiratory syncytial virus (RSV). Palivizumab (Synagis(®)), a humanized IgG1 monoclonal antibody (mAb) approved for RSV immunoprophylaxis in at-risk neonates, is highly effective, but pharmacoeconomic analyses suggest its use may not be cost-effective. Previously described potent RSV neutralizers (human Fab R19 and F2-5; human IgG RF-1 and RF-2) were produced in IgG format in a rapid and inexpensive Nicotiana-based manufacturing system for comparison with palivizumab...
March 2013: MAbs
https://www.readbyqxmd.com/read/23302182/a-cell-based-high-throughput-screening-approach-for-the-discovery-of-new-inhibitors-of-respiratory-syncytial-virus
#16
Dong-Hoon Chung, Blake P Moore, Daljit S Matharu, Jennifer E Golden, Clinton Maddox, Lynn Rasmussen, Melinda I Sosa, Subramaniam Ananthan, E Lucile White, Fuli Jia, Colleen B Jonsson, William E Severson
BACKGROUND: Human respiratory syncytial virus (hRSV) is a highly contagious pathogen and is the most common cause of bronchiolitis and pneumonia for infants and children under one year of age. Worldwide, greater than 33 million children under five years of age are affected by hRSV resulting in three million hospitalizations and 200,000 deaths. However, severe lower respiratory tract disease may occur at any age, especially among the elderly or those with compromised cardiac, pulmonary, or immune systems...
2013: Virology Journal
https://www.readbyqxmd.com/read/22336832/palivizumab-for-prophylaxis-against-respiratory-syncytial-virus-infection-in-children-with-cystic-fibrosis
#17
REVIEW
Karen A Robinson, Olaide A Odelola, Ian J Saldanha, Naomi A McKoy
BACKGROUND: Respiratory syncytial virus infection causes acute lung infection in infants and young children worldwide, resulting in considerable morbidity and mortality. Children with cystic fibrosis are prone to recurrent lung inflammation, bacterial colonisation and subsequent chronic airway disease, putting them at risk for severe respiratory syncytial virus infections requiring intensive care and respiratory support. No treatment currently exists, hence prevention is important. Palivizumab is effective in reducing respiratory syncytial virus hospitalisation rates and is recommended for prophylaxis in high-risk children with other conditions...
2012: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/22335496/targeting-rsv-with-vaccines-and-small-molecule-drugs
#18
REVIEW
Heather M Costello, William C Ray, Supranee Chaiwatpongsakorn, Mark E Peeples
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein...
April 2012: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/21281564/palivizumab-for-immunoprophylaxis-of-respiratory-syncytial-virus-rsv-bronchiolitis-in-high-risk-infants-and-young-children-a-systematic-review-and-additional-economic-modelling-of-subgroup-analyses
#19
REVIEW
D Wang, S Bayliss, C Meads
BACKGROUND: Respiratory syncytial virus (RSV) is a seasonal infectious disease, with epidemics occurring annually from October to March in the UK. It is a very common infection in infants and young children and can lead to hospitalisation, particularly in those who are premature or who have chronic lung disease (CLD) or congenital heart disease (CHD). Palivizumab (Synagis®, MedImmune) is a monoclonal antibody designed to provide passive immunity against RSV and thereby prevent or reduce the severity of RSV infection...
January 2011: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/20824840/withdrawn-immunoglobulin-treatment-for-respiratory-syncytial-virus-infection
#20
REVIEW
Hannah L Fuller, Chris B Del Mar
BACKGROUND: Respiratory syncytial virus (RSV) bronchiolitis and pneumonia hospitalise hundreds of thousands of infants every year. Treatment is largely supportive therapy, (for example, oxygen, fluids and occasionally mechanical ventilation). Ribavirin, an antiviral agent, is licensed for severe RSV infection, although systematic reviews find it of no benefit. Passive protection against RSV can be achieved through monthly intramuscular injections of the humanised monoclonal anti-RSV antibody palivizumab (Synagis), and yields a 55% reduction in RSV hospitalisation in susceptible infants...
2010: Cochrane Database of Systematic Reviews
keyword
keyword
55972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"